Medtronic cuts 40 jobs in Minnesota; Battelle acquires stake in medical isotopes company;

@FierceMedDev: ICYMI yesterday: FDA lowers regulatory bar for neurostimulators to treat headache. Story | Follow @FierceMedDev

@StacyALawrence: Boston Scientific backs Israeli cardio device startup Mvalve with $15M. More | Follow @StacyALawrence

@VarunSaxena2: Check out our special report on the top 10 highest paid med tech CEOs. Feature | Follow @VarunSaxena2

@MichaelGFierce: A tiny, "walking" robot powered by a muscle cell? It could help deliver drugs one day. FierceDrugDelivery story | Follow @MichaelGFierce

@EmilyWFierce: Rapid Dx tests for Chagas disease yield quick, reliable results without lab confirmation, according to study. New York Times article | Follow @EmilyWFierce

> Although Medtronic ($MDT) says it plans to create 1,000 jobs in Minnesota after completing its acquisition of Covidien ($COV), a state agency recently disclosed 40 job cuts from the company's Minnesota offices in Fridley and Mounds View. Story

> Brachytherapy devices and medical isotopes company Advanced Medical Isotope Corporation announced that nonprofit science and technology company Battelle has acquired about 11% of the company's shares. More

> The FDA announced the Class I recall of certain models of Vascular Solution's ($VASC) Langston V2 Dual Lumen Catheters after reports of the inner catheter becoming disconnected from the body of the device. Report

> Veran Medical has raised $6.5M since November 2013 in support of the development of the next iteration of its FDA-cleared device for the early detection of lung cancer. More

Biotech News

@FierceBiotech: AstraZeneca spreads its virtual reach to cardio R&D with new partnership. News | Follow @FierceBiotech

@JohnCFierce: Intent on closing a deal, AbbVie boosts its bid for Shire to $51B. News | Follow @JohnCFierce

@DamianFierce: So $SHPG has 10 days to consider $ABBV's +11% offer. Press release | Follow @DamianFierce

@EmilyMFierce: European neuroscientists ask for better governance and tough review in EU Human Brain Project. Science story | Follow @EmilyMFierce

> Lilly partners with China's Yabao on diabetes drug. Item

> Boehringer's 'breakthrough' cancer drug comes through in Phase II. Report

> Versant close to capping $300M fund to foster next-gen biotechs. Article

> Novartis' leading CAR-T cancer therapy gains 'breakthrough' status at the FDA. Story

Pharma News

@FiercePharma: Top-read on FP Monday: EU approves GSK's Mekinist and Novartis will reap the rewards. Article | Follow @FiercePharma

@EricPFierce: Health Canada tells GSK to get its vaccine house in order as flu season approaches. Story | Follow @EricPFierce

@CarlyHFierce: ICYMI: Ackman puts forth his slate of new Allergan directors. Report | Follow @CarlyHFierce

> AbbVie puts $51.5B on the table in fourth go at Shire. More

> Novartis accused again of kickback tactics in new whistleblower suit. Report

> Merck attacks Italian critic of cholesterol fighter Zetia, then backs off. Article

Biotech Research News

> Schizophrenia-linked genetic variation causes abnormal brain cell development. More

> Blocking cell migration could stop cancer spread. Article

> Technique regrows corneas in mice from adult human stem cells. Story

> Chemical switch could be drug target for neurodegenerative disease. More

> AstraZeneca, MRC Technology renew preclinical pact. Item

Pharma Manufacturing News

> Cipla plans U.K. investment as Indian drugmakers await economic reforms. More

> Ingredient price hikes prompt Express Scripts to slash coverage of compounded drugs. Story

> Novo A/S-owned Xellia snaps up Fresenius vial plant to expand in U.S. Report

> Hospira completes Orchid plant takeover to boost API supply security. Item

> Ingredient price hikes prompt Express Scripts to slash coverage of compounded drugs. Story

> Health Canada gives GSK 30 days to show how it will fix its vaccine plant. Article

Suggested Articles

Qiagen launched a one-stop shop compiling publicly available genomic data, scientific literature and phenotypic information on potential superbugs.

Adaptive Biotechnologies is planning a $200 million IPO to help power its sequencing tests aimed at the body’s immune system and related therapies.

Abbott’s new diabetes test provides A1c results in three minutes, allowing clinicians to develop care plans within a single office visit.